

30 APR 1959

Mr. O. R. Dudley *-carel*

Dear Mr. Dudley:

I very much appreciate your letter of April 18th together with the enclosed book and your kind remarks concerning my brother.

It was very considerate of you to write and you can be sure that your suggestions, as well as those of many other thoughtful persons like yourself, are being given careful attention and consideration.

I am returning your book since I find there are other copies of it available here.

With best wishes.

Sincerely,

Allen W. Dulles
Director

Enclosure:

O/DCI [] rad 29 Apr 59

Distribution:

Orig - Addressee w/encl
1 - DCI
1 - FMC
-1 - ER w/basic

April 18, 1959

Dear Mr. Dulles,

This book goes into the case histories of people that had Krebiozen administered to them. There is another book titled "Matter of Life or Death" by Herbert Bailey that goes into the cloak and dagger story on why Krebiozen is being held from the general public. The fastest way to get this other book is through the library.

Your brother needs this long now and I pray that you will get quick action for his sake.

The doctors around you will tell you "K" isn't any good, but asked them if they have personally given "K". Doctors are not beyond lying so a ~~doctor~~ ^{physician} ~~should~~ ^{must} tell the truth.

O.R. Puller

Krebiozen Backers to Ask Funds, Make More of Cancer Preparation

Plan Drive For \$350,000

BY ARTHUR J. SNIDER
Daily News Science Writer

Krebiozen backers are adopting the pattern of heart, tuberculosis and other fund-raising societies and seeking public contributions.

For the first time, a general drive for money will be launched to manufacture more of the drug.

Dr. Andrew C. Ivy, University of Illinois physiologist and research director of the Krebiozen Research Foundation, said at least \$350,000 will be needed.



The present supplies, manufactured by Dr. Steven and Marko Durovic, immigrants from South America, will be exhausted this summer, Ivy told a testimonial dinner Monday night in the Morrison hotel.

The money will be collected by a new non-profit, tax-exempt organization to be formed by John M. Davis, president of the LaSalle Construction Co. and of the Committee for a Fair Test for Krebiozen.

Davis said it will have nothing to do with the Durovics' pharmaceutical company known as Duga.


IVY'S REQUEST for more Krebiozen was made before 1,100 persons attending the dinner, including some 40 patients now receiving it.

"Those patients now dependent on Krebiozen will be left without it next summer," said Ivy.

"Who then will be responsible for the consequences of taking away their Krebiozen? Not me, because I am going to work and appeal to others to help make a new batch."

IVY ALSO renewed his demand for a "fair test" of the drug under an evaluation set-up that would include himself as one of the three testers.

He has rejected a counter-proposal that an independent



Dr. Andrew C. Ivy (right), research director of the Krebiozen Research Foundation, introduces cancer patients who, Dr. Ivy says, have been benefited by the controversial drug. The introduce-

tions were made at a testimonial dinner for Dr. Ivy in the Morrison hotel, attended by more than 1,000 persons. Left to right are H. W. Nepo, Gary Cathcart and La Rayne Graham.

five-man committee make the test.

Negotiations are currently under way with the National Cancer Institute in Washington.

"If we cannot get a fair test under the auspices of the National Cancer Institute under existing legislation, then new legislation will be sought," Ivy said.

IVY LATER explained this would be congressional action requiring the National Cancer Institute to test the drug under a specific method.

Sen. Douglas (D., Ill.), one of the speakers, expressed hope the issue would be settled before it came to congressional action.

IVY SAID he cannot agree to an "independent group" because he felt none could be

selected that did not have a "bias."

IVY REVIEWED results of Krebiozen treatments on 1,000 patients. Figures he has compiled, he said, indicate that pain was abolished or markedly relieved in 300.

The size of the tumor, he added, was decreased for a variable period in 500. Some 250 bedridden patients have become ambulatory, according to Ivy. About 10 per cent, he said, have been alive four to eight years.

DR. IVY WAS the hero of the rapt audience—but some of the cancer patients introduced had great emotional impact on the audience.

One of them, Jay Pearlman, 19, of 2010 Arthur told a reporter:

"Should Krebiozen be

can be saved as I was saved.


"If Krebiozen could save 10 out of 100, it would be worth it."

Jay was introduced as one of Krebiozen's successes. Dr. Ivy said the young man suffered a brain stem tumor, underwent surgery and was a "vegetable" when Krebiozen treatment began.

Today Jay walks and talks and goes to school.

tested? Of course. My only wish is that other people

STAT



Mr. Allen W. Dulles
Central Intelligence Agency
Washington
D. C.

Personal